Evidence map›Paper›PMID 23246507›Full record

ArticleJournal of hepatology2013

Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling.

Harel Dahari, Scott J Cotler, Thomas J Layden, Alan S Perelson

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Harel Dahari
Scott J Cotler
Thomas J Layden
Alan S Perelson

Funding

UNM COBRE: THEORETICAL STUDY OF SPECIFICITY OF RNA SILENCING MECHANISMP20RR018754 · NCRR · UNIVERSITY OF NEW MEXICO · PI LOKER, ERIC SAMUEL · 2003 to 2011
$16.7M
Collaborative Integration of HCV Molecular Virology and Mathematical ModelingR01AI078881 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PERELSON, ALAN S, UPRICHARD, SUSAN L. · 2011 to 2025
$7.5M
HIV Antiretroviral Therapy and Hepatic InjuryR01AI065256 · NIAID · UNIVERSITY OF CINCINNATI · PI SHERMAN, KENNETH E · 2006 to 2019
$5.5M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
Immune System Modeling/HIVR37AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 2002 to 2011
$2.4M
HIV Antiretroviral Therapy and Hepatic InjuryR56AI065256 · NIAID · UNIVERSITY OF CINCINNATI · PI SHERMAN, KENNETH E · 2014 to 2014
$535k
Collaborative Integration of HCV Molecular Virology and Mathematical ModelingR56AI078881 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PERELSON, ALAN S, UPRICHARD, SUSAN L. · 2010 to 2010
$421k
NCRR NIH HHS P20 RR018754NCRR NIH HHS P20-RR018754NIAID NIH HHS AI028433NIAID NIH HHS AI065256NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI065256NIAID NIH HHS R01 AI078881NIAID NIH HHS R37 AI028433NIAID NIH HHS R56 AI065256NIAID NIH HHS R56 AI078881NIAID NIH HHS R56/R01-AI078881NIH HHS OD011095NIH HHS R01 OD011095
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Polymorphism, Single NucleotideFemaleHepacivirusHepatitis C, ChronicHumansInterleukinsMaleInterleukins

Identifiers

PMID23246507
PMCPMC3667977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.